Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle
- 46 Downloads
Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cells transplantation, occurring in about half of transplanted patients. This condition seems to be the result of a progressive immune-mediated damage that can involve various tissues, including the eyes. The ocular surface system is the ocular structure most frequently impaired, and dry eye disease is considered the hallmark of ocular GVHD. Given the increasing prevalence and the frequent severe involvement of the ocular surface with vision-threatening complications, ocular GVHD represents a current diagnostic and therapeutic challenge. The purpose of this literature review is to describe all the clinical manifestations occurring in the setting of ocular GVHD, and to further report the outcomes of conventional and novel therapies.
A literature search about ocular GVHD was performed in PubMed, Scopus, Medline databases, and ClinicalTrials.gov as well as through the reference lists of identified publications until January 2019. We have included RCTs, prospective observational studies, prospective and retrospective cohort studies, pilot studies, and review articles.
Overall, 107 articles, 3 book chapters, and 6 ongoing registered clinical trials were collected and analyzed. Ocular GVHD can affect all the structures of the entire ocular surface system, including lacrimal and meibomian glands, cornea, conjunctiva, eyelids, nasolacrimal duct, and tears. Current medical treatment is mainly focused on lubrication and control of drainage, tear evaporation, and ocular surface inflammation. Surgical treatment may be necessary in severe, recalcitrant, or complicated cases. Amniotic membrane and tectonic keratoplasty can be valid options to restore the integrity of the cornea. Recently, conjunctival and limbal transplantation from the same living-related bone marrow donor has been proposed to manage both dry eye and limbal stem cell deficiency, without any risk of immunologic rejection.
This review provides an up-to-date analysis on clinical findings and current and future management of ocular GVHD. A correct and prompt diagnosis along with an appropriate and aggressive treatment are fundamental for avoiding the occurrence of vision-threatening complications.
KeywordsOcular graft-versus-host disease Allogeneic stem cell transplantation Bone marrow transplantation Dry eye Ocular surface system
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
- 30.Que L, Zhang X, Li M (2017) Single-center retrospective study on meibomian gland loss in patients with ocular chronic graft-versus-host disease. Eye Contact Lens 0:1–7Google Scholar
- 41.Giannaccare G, Pellegrini M, Sebastiani S, Moscardelli F, Versura P, Campos EC (2019) In vivo confocal microscopy morphometric analysis of corneal subbasal nerve plexus in dry eye disease using newly developed fully automated system. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-018-04225-7
- 54.Sullivan KM (1999) Graft-versus-host-disease. In: Forman SJ (ed) Hematopoietic cell transplantation. Blackwell, Oxford, pp 515–536Google Scholar
- 55.Jabs DA (1996) Ocular complications of bone marrow transplantation. In: Pepose J, Wilhelmus K (eds) Ocular infection and immunity. Mosby, St. Louis, pp 426–434Google Scholar
- 56.Kim SK (2004) Ocular graft versus host disease. In: Krachmer JH, Mannis MJ, Holland EJ (eds) Cornea. Mosby, St Louis, pp 879–885Google Scholar
- 71.Schargus M, Meyer-ter-Vehn T, Menrath J, Grigoleit GU, Geerling G (2015) Correlation between tear film osmolarity and the disease score of the International Chronic Ocular Graft-Versus-Host-Disease Consensus Group in hematopoietic stem cell transplantation patients. Cornea 34:911–916CrossRefPubMedGoogle Scholar
- 72.Carpenter PA, Kitko CL, Elad S et al (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 21:1167–1187CrossRefPubMedPubMedCentralGoogle Scholar
- 79.Giannaccare G, Pellegrini M, Sebastiani S et al (2019) Efficacy of omega-3 fatty acid supplementation for the treatment of dry eye disease: a meta-analysis of randomized controlled trials. Cornea. https://doi.org/10.1097/ICO.0000000000001884
- 81.Inamoto Y, Petricek I, Burns L et al (2018) Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. https://doi.org/10.1038/s41409-018-0339-6
- 86.Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI (2015) Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea 34:725–732CrossRefPubMedGoogle Scholar